%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-05-11T18:12Z
2024-03-29T03:22:47-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T03:22:47-07:00
application/pdf
Heather
2003-577.june
uuid:e0d97694-1dd1-11b2-0a00-430827edca00
uuid:e0d97697-1dd1-11b2-0a00-380000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
102 0 obj
[106 0 R]
endobj
103 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.1132 Tw 10 0 0 10 54 713.1616 Tm
[(anxiety)64.8 (, which was not associated with either of the acute)]TJ
0.02499 Tw 0 -1.2 TD
(phase reactants.)Tj
/T1_2 1 Tf
0.01961 Tw 0 -1.44 TD
[(Discor)36.8 (dance between hs-CRP)-251.9 (and ESR.)]TJ
/T1_1 1 Tf
16.243 0 Td
(The correlation \(R\))Tj
0.08189 Tw -16.243 -1.2 Td
[(between hs-CRP)-295.2 (and ESR was 0.61)36.7 (1. )54.8 (All patients \(n = 18,)]TJ
0.1871 Tw 0 -1.2 TD
[(12%\) with an hs-CRP)-400.3 (> 23 mg/l had a high ESR \(> 20)]TJ
0.0083 Tc 0.36659 Tw T*
[(mm/h\). )17.7 (The discordance in the remaining 128 \(88%\))]TJ
-0.00011 Tc 0.09219 Tw T*
(patients is shown in Figure 1. Most patients with an inter-)Tj
0.02499 Tw T*
[(mediate or low hs-CRP)-238.3 (did not have a high ESR.)]TJ
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(DISCUSSION)Tj
/T1_1 1 Tf
0.0762 Tw 0 -1.2 TD
[(The use of hs-CRP)-289.4 (assays was recently recommended as a)]TJ
0.0005 Tw T*
(measure to identify low disease activity in RA)Tj
0 Tc 0 Tw 6.5 0 0 6.5 239.255 582.0616 Tm
[(3,1)56.7 (1)]TJ
-0.0173 Tw 10 0 0 10 250.2612 578.7616 Tm
[(. W)80 (e)0.1 ( )-17.8 (found)]TJ
-0.00011 Tc 0.0695 Tw -19.6261 -1.2 Td
[(that in 61 \(42%\) of our patients, the hs-CRP)-282.7 (was 2\3208 mg/l)]TJ
0.1792 Tw T*
[(and the hs-CRP)-392.4 (was predictive of disease activity)64.8 (. )17.7 (These)]TJ
0.2104 Tw T*
(patients were also less often in clinical remission)Tj
0 Tc 0 Tw 6.5 0 0 6.5 264.4881 546.0616 Tm
(6)Tj
-0.00011 Tc 10 0 0 10 272.3425 542.7616 Tm
(when)Tj
0.1456 Tw -21.8343 -1.2 Td
[(compared to patients with an hs-CRP)-358.8 (< 2 mg/l. Systemic)]TJ
0.25909 Tw T*
(inflammation that is generally not detectable by routine)Tj
0.3007 Tw T*
[(CRP)-514 (testing may be common in RA. Since even mild)]TJ
-0.01289 Tw T*
(disease activity is associated with poor longterm outcome in)Tj
0 Tw T*
(RA)Tj
0 Tc 6.5 0 0 6.5 67.8892 486.0616 Tm
(1)Tj
-0.00011 Tc 0.05141 Tw 10 0 0 10 71.1391 482.7616 Tm
[(, hs-CRP)-264.6 (testing should be helpful in deciding whether)]TJ
0.02499 Tw -1.7139 -1.2 Td
(disease modifying agent therapy needs intensification. )Tj
0.1333 Tw 1.2 -1.2 Td
[(Of interest, even in patients with an hs-CRP)-346.6 (< 2 mg/l,)]TJ
0.0284 Tw -1.2 -1.2 Td
[(only 50% met the )54.8 (ACR criteria for clinical remission)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 267.8684 450.0616 Tm
(6)Tj
-0.00011 Tc 0.0107 Tw 10 0 0 10 271.1184 446.7616 Tm
(. This)Tj
-0.0079 Tw -21.7118 -1.2 Td
(may indicate that reliance on the acute phase response alone)Tj
-0.02 Tw T*
(is inadequate in monitoring disease activity and supports the)Tj
0.2023 Tw T*
(use of multiple measures in assessing disease activity in)Tj
0 Tw T*
(RA)Tj
0 Tc 6.5 0 0 6.5 67.8892 402.0616 Tm
[(1,2,1)56.7 (1-13)]TJ
10 0 0 10 92.4332 398.7616 Tm
(. )Tj
-0.00011 Tc 0.0322 Tw -2.6433 -1.2 Td
[(W)79.9 (e further found that the hs-CRP)-245.4 (was consistently more)]TJ
-0.0264 Tw -1.2 -1.2 Td
(strongly associated with other disease activity variables than)Tj
-0.02071 Tw T*
[(the ESR. CRP)-192.6 (and ESR were previously reported to be asso-)]TJ
0.15311 Tw T*
(ciated to a similar extent with disease activity in RA)Tj
0 Tc 0 Tw 6.5 0 0 6.5 276.8753 354.0616 Tm
(12,13)Tj
10 0 0 10 291.5002 350.7616 Tm
(.)Tj
-0.00011 Tc -0.0031 Tw -23.75 -1.2 Td
[(Whether this discrepancy relates to dif)17.7 (ferences in the assays)]TJ
0.02499 Tw T*
[(being used may need further study)64.8 (.)]TJ
0.3714 Tw 1.2 -1.2 Td
[(In conclusion, by using an hs-CRP)-584.7 (assay)64.8 (, systemic)]TJ
0.14799 Tw -1.2 -1.2 Td
(inflammation that is generally not detectable with routine)Tj
0.3241 Tw 26.4 41.04 Td
[(CRP)-537.3 (tests was commonly found in RA. )54.9 (Also, hs-CRP)]TJ
0.2115 Tw T*
(performed consistently better than the ESR at predicting)Tj
0.02499 Tw T*
(other disease activity variables.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 318 655.1616 Tm
[(W)79.9 (e wish to thank Dr)54.8 (. K. Reddi for revising the manuscript)]TJ
0 Tc 0 Tw 10 0 0 10 506.8614 655.1615 Tm
(.)Tj
/T1_3 1 Tf
-0.00011 Tc -18.8861 -2.4 Td
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 325 621.1616 Tm
[(1.)-875.1 (W)79.9 (olfe R, Cush JJ, O\325Dell JR, et al. Consensus recommendations for)]TJ
1.675 -1.25 Td
(the assessment and treatment of rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw 0 -1.25 TD
(2001;28:1423-30.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Fransen J, Stucki G, van Riel P)110.7 (.)-0.1 ( )17.7 (The merits of monitoring: should)]TJ
1.675 -1.25 Td
(we follow all our rheumatoid arthritis patients in daily practice?)Tj
T*
(Rheumatology 2002;41:601-4.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Sharif M, Elson C, Kirwan J. Sensitive C-reactive protein in)]TJ
1.675 -1.25 Td
(arthritis. BMJ 2001;322:4-5. )Tj
-1.675 -1.25 Td
[(4.)-875.1 (Ridker PM, Cushman M, Stempfer MJ, et al. Inflammation, aspirin,)]TJ
1.675 -1.25 Td
(and the risk of cardiovascular disease in apparently healthy men. )Tj
0 Tc T*
(N Engl J Med 1997;336:973-9.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatology )54.8 (Association 1987 revised criteria for the )]TJ
T*
[(classification of rheumatoid arthritis. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(1988;31:315-24.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Pinals RS, Masi )54.8 (A)110.8 (T)74 (, Larsen RA, et al. Preliminary criteria for )]TJ
1.675 -1.25 Td
[(clinical remission in rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1981;24:1308-15.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Bruce B, Fries JF)79.7 (. )17.7 (The Stanford Health )54.8 (Assessment Questionnaire:)]TJ
1.675 -1.25 Td
[(a review of its history)64.8 (, issues, progress, and documentation. )]TJ
T*
(J Rheumatol 2003;30:167-78.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Egger MJ, Huth DA, )17.7 (W)79.9 (ard JR, Reading JC, )17.7 (W)39.8 (illiams HJ. Reduced)]TJ
1.675 -1.25 Td
(joint count indices in the evaluation of rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1985;28:613-9.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Pincus )17.7 (T)74 (, Brooks RH, Callahan LF)79.7 (. Prediction of long-term)]TJ
1.675 -1.25 Td
(mortality in patients with rheumatoid arthritis according to simple)Tj
T*
[(questionnaire and joint count measures. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1994;120:26-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Pincus )17.7 (T)74 (, Swearingen C, )17.7 (W)79.9 (olfe F)79.7 (.)-0.1 ( )17.7 (T)69.9 (oward a Multidimensional)]TJ
2.175 -1.25 Td
[(Health )54.8 (Assessment Questionnaire \(MDHAQ\). )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:2220-30.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Fransen J, )17.7 (W)79.9 (elsing PMJ, De Keijzer RMH, )17.7 (V)110.8 (an Riel PLCM.)]TJ
2.1381 -1.25 Td
[(Development and validation of the DAS28 using CRP)110.7 (. )54.8 (Ann Rheum)]TJ
0 Tc T*
(Dis 2003;62 Suppl 1:10.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (W)79.9 (olfe F)79.7 (. Comparative usefulness of C-reactive protein and )]TJ
2.175 -1.25 Td
(erythrocyte sedimentation rate in patients with rheumatoid arthritis.)Tj
T*
(J Rheumatol 1997;24:1477-85.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Paulus HE, Ramos B, )17.7 (W)79.9 (ong )17.7 (WK, et al. Equivalence of the acute)]TJ
2.175 -1.25 Td
[(phase reactants C-reactive protein, plasma viscosity)64.8 (, and)]TJ
T*
[(W)79.9 (ester)17.7 (gren erythrocyte sedimentation rate when used to calculate)]TJ
T*
(American College of Rheumatology 20% improvement criteria or)Tj
T*
(the disease activity score in patients with early rheumatoid arthritis.)Tj
T*
(J Rheumatol 1999;26:2324-31.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Dessein, et al: High sensitivity CRP)-257.3 (in RA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1097)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
47 291 255 -224 re
W* n
q
/Fm0 Do
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc 0.0578 Tw 8 0 0 8 54 85.5297 Tm
[(Figur)36.8 (e 1.)]TJ
/T1_1 1 Tf
4.0501 0 Td
[(Discordance between ESR and hs-CRP)-271 (in 128 RA)-252.9 (patients with)]TJ
0.02499 Tw -4.0501 -1.25 Td
[(hs-CRP)-238.2 (< 23 mg/l.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\7!Kt>C#iu"-j?#t-e=S@+C]QOd7c
l+.ffOc=J&qHc%.qL,#Y;5PJ(0$E7;G?lJYi8?eu6`AqHKNFYSFnEso>du,icc_eY
CoMkhdMUMsT_ZJ3h30pW3A6UjM%(R_[sSEmOWGaQA.;NV%'GB9/G=LNdLd2$Y%:^/"#Z.3NY4`Ah-*
?A=@23hJPC=;r-Za$&1K(Dn[l'AYe%F@#0^mAhScE__PZCG^j<*L*M_foQ]"L03jP
@!RUX!ED33BKW1/jNuJH(bjEj`r*-Kq6i/f@2iNYC&"WrJXS38+sR3P)LWW'lm:o"
W]V*!B]!9h.G\bT%ce3X'GUN7_[i8\V9eo5BeV'f'QplkL10g6liIAUCn8
ZeM$s]tYr7-`?r`C):E4GY0!=CK4K-r5
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
11 0 obj
<>stream
H$
@@'8pʘ{m^R@p!B&1W
&wx~+7N蒆&LqCn@z A
endstream
endobj
10 0 obj
<1.3<>>>
endobj
8 0 obj
<>/ProcSet[/PDF/ImageB]/XObject<>>>
endobj
7 0 obj
<>/Filter/CCITTFaxDecode/Height 783/ImageMask true/Length 3119/Subtype/Image/Type/XObject/Width 1047>>stream
[!JMpAJ_p^4yA__Ҟ03fYg9-8֤d$!,&a}=5p_#_|>oo{_]0gcW"ATN.-h&i>8d]Կ66Wڿmuޤ*>ǿY6EpGղ1~Z\0X"?KMbM/s^Oz?k?>OzE4\QqA7 [Oz}xKIQ__!?t=ʏz_C=`9? R ___wm{Z_տZ_Wk#>OzYaOz2qOoi?oZ_Gzvd?aakL&G_s_!T_?;3җA4iK>?k`UA}{8_OzoKߑIa&^cޢ>}Z,OkMאV>|/T}2Ό&-7 i_Ҵ H0MtZǧ5o_I/kч_wI~K/zIH}1^_sS!e+Ih0?k%hqO24?i.{/Uo?N[z~TAzowFm'v_<]PZz|%?)_ɇu
a8*+aEy6\uB~駵<0__!w?^I .v t!Wi]_լ(~5eLUi4i]\=}OC 2
_6q⍉q@}}{-P\QeACַ&̏ :_[Me\R@/-lKq6a]+KA0~+0_M_~Ή`!WZiYQUM5M7XoκuTes= ݠriᄛ3N?j8bA^IӴ ;.$DA
KOULJev+'%l;Ҵk:/<0鸵?ꍏMUM|/5监A駆aa0p+?4iW1~^?~~HIA_E=Aޘ؎,/_?m-[%
4vZdǫ)Uk]?(sTL Pm5e,t_w
ѕol-4Iǵ? &FH6xMGW, tu8i
7heh'GL04Lc_O75oA״mQLUӻq(
_
i)?FS{w^w^v~EqwMm:)iI4PE8GU~גp1]Ȟ5dgr#=1F"!#~~)#̌##jiѱ~F>5_i_@]ș,
"Ď쎌/W*)ѼDq\ ȑ2ZD9"#iұ#fwvuL 8ɤN3\ՓLn4Tie,Ael*.nU5L&A-ޓtA ڪ....&T.ji6xAmh_ڨZpi6/[徴[чc]*5Z\/פP돏([i$K
WrZ^U_mo.O/IuK_v+DנKKzKV^K_ߥ] KZVK:zIl% i6~붩zUb%"_ۯJ5Z0k ADD4Tح^YTM4k-PdySͣ~
pӻIv/7å]}s4FQ/xh0#E"?I;gaVt=E_|*&c78/_oW7䇷v_&KmkiGM7auʥ5k}/mWa0C
endstream
endobj
72 0 obj
<>
endobj
9 0 obj
<>
endobj
85 0 obj
<>
endobj
42 0 obj
<>
endobj
40 0 obj
<>
endobj
47 0 obj
<>
endobj
78 0 obj
<>
endobj
97 0 obj
<>
endobj
48 0 obj
<>
endobj
73 0 obj
<>stream
H\TkPWv辰=35X*l 1Q adaf`f@QP
QYV4+X1nNgnuNuݺ|w
(*4nQBذlmJ՜FH:4x4"HQhy^|^
ao )*xxDxYs
g&͎9Yl%7Ħ[
mla%*X\cT!l6,U2K6/Tj0\!5ݘ*dDŚ[c4ľkHm&-o͔nJLF˻
ˁWH(yƩT t*R!K
RUMyd~M]NОt:#aLs\RE*EtxA!ЙSlZm ]9YC7)6[[X;pfp>A'wC3/Ej=Wgחϸx0&ʋ1lYΙi:bH(rBK >
qyH@E% 9q/wB2
,fP \'_ x_2BkfWE'0spo0x,M!Nhz%
gw ->+&w7|!{:.qĜ0glcF#C [,UN^+3;""2Q3R@:\eH#O{;<^?$yL'$(IR3Y>2ψ2Ĉi
_=]^9Svu3ݹBS9p/D)p-{jQ}َ`[֒oOe/ +Qb]cܴPJrAUb3`sP0H,0{yzL~l\UY lZgs@ gR=~>E.ؕHRc34k%p+Yh"FDV]$/Oe'=ZM'&Cv?I㽄KKzqo%굋9<&o)fOlgBX/+6jZe
jim8'p&hl`>AgX`L *I023a,PllfoAzmV?DAYvSX)%}vFxcoBfVxC`;3@}m$D25